Discovery Labs Anticipates Surfaxin Approval In 2008 For Respiratory Distress Syndrome
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm is resolving outstanding manufacturing issues with the synthetic surfactant, with plans to submit six-month stability data in a “complete response” to FDA.
You may also be interested in...
Discovery Enters Phase II Trial Of Surfaxin For Acute Respiratory Failure In Children
Firm takes next step in its goal to develop compound for wide range of respiratory problems in children and adults.
Discovery Enters Phase II Trial Of Surfaxin For Acute Respiratory Failure In Children
Firm takes next step in its goal to develop compound for wide range of respiratory problems in children and adults.
Discovery Labs Pulls Surfaxin Application In EU, Citing Manufacturing, Data Issues
The firm may be required to conduct additional clinical trials comparing lucinactant to the leading EU surfactant, Curosurf.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: